Teva Canada announces launch of generic version of Abilify

Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries, announces that the complete line of Teva-Aripiprazole, a Health Canada approved, bioequivalent generic version of Abilify is now available in Canada. This once-daily extended release prescription medication is indicated for the treatment of schizophrenia in adolescents 15-17 years of age and adults 18 years of age or older. Aripiprazole tablets had annual sales of approximately $182M in Canada, based on IQVIA sales data as of July 2018. Teva-Aripiprazole is available immediately to pharmacies across Canada. This launch broadens Teva Canada’s portfolio of medicines that treat mental health conditions to 28, including seven in the same therapeutic class as Teva-Aripiprazole, all of which provide patients and payors with a full spectrum of affordable treatment options.
https://thefly.com/landingPageNews.php?id=2788101